Gilead Sciences has said it hopes to start trials in August of an easier-to-use inhaled version of remdesivir, currently administered only intravenously.from Moneycontrol Business News https://ift.tt/2CyinZV
Monday, June 22, 2020
Subscribe to:
Post Comments (Atom)
-
The value had touched a high of 22% of total market capitalisation of listed firms in June 2009, dropping to a low of 5.1% in September 2020...
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment